Nervgen Pharma Corp (NGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2004 | 03-2004 | 12-2003 | 09-2003 | 06-2003 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -18,260 | -5,370 | -30,590 | -24,650 | -17,570 |
| Depreciation Amortization | 1,790 | 850 | 4,660 | 3,420 | 2,180 |
| Other Working Capital | -2,870 | -690 | -1,180 | -1,450 | -2,840 |
| Other Operating Activity | 4,180 | -1,160 | 1,640 | 2,510 | 2,740 |
| Operating Cash Flow | $-15,160 | $-6,370 | $-25,470 | $-20,170 | $-15,490 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -140 | -120 | -1,170 | -1,090 | -720 |
| Net Acquisitions | -2,360 | 0 | 0 | 0 | 0 |
| Other Investing Activity | -31,480 | -11,230 | 16,610 | 17,400 | 12,590 |
| Investing Cash Flow | $-33,980 | $-11,350 | $15,440 | $16,310 | $11,870 |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | 49,100 | 41,060 | 8,930 | 7,070 | -280 |
| Financing Cash Flow | $49,100 | $41,060 | $8,930 | $7,070 | $-280 |
| Exchange Rate Effect | 20 | 140 | 290 | 190 | 190 |
| Beginning Cash Position | 8,550 | 8,550 | 9,350 | 9,350 | 9,350 |
| End Cash Position | 8,540 | 32,030 | 8,550 | 12,760 | 5,630 |
| Net Cash Flow | $-7 | $23,480 | $-800 | $3,410 | $-3,710 |
| Free Cash Flow | |||||
| Operating Cash Flow | -15,160 | -6,370 | -25,470 | -20,170 | -15,490 |
| Free Cash Flow | -15,160 | -6,370 | -25,470 | -20,170 | -15,490 |